Le Lézard
Classified in: Health, Business
Subject: VEN

Shorla Pharma Closes $8.3M Series A Funding Round


DUBLIN and CLONMEL, Ireland, June 3, 2020 /PRNewswire/ -- Shorla Pharma Limited ('Shorla'), an Irish specialty pharmaceutical company, has today announced the completion of a Series A investment of $8.3 million. The financing was led by Seroba Life Sciences ('Seroba'), a European Venture Capital firm headquartered in Dublin, Ireland with additional investment from Irish and Canadian based family offices and participation from Enterprise Ireland.

Shorla has developed innovative oncology drugs with a focus on rare, orphan and pediatric cancers, delivering more effective products in indications where existing treatments are sub-optimal for the target patients.

The company was founded by Sharon Cunningham and Orlaith Ryan ('Shorla' is a combination of both first names), both formerly with EirGen Pharma ('EirGen') in Waterford, Ireland. Shorla is based in Questum, a Clonmel, Ireland based acceleration center.

Together with a strong team of scientists, clinicians and an extensive industry network, the company has an advanced pipeline of innovative drug products to treat a number of unmet patient needs. The funding will support the advancement of the product pipeline, along with expansion of technical and commercial operations in both Ireland and the US.

Alan O'Connell, a Partner at Seroba who has joined the Shorla board, said, "We're delighted to support an Irish company with such a promising pipeline of products designed to improve treatment options for cancer patients. Shorla is led by experienced founders with a track record of success in the sector and we look forward to working with them to grow the company and bring their products to market."

Speaking about the investment, Orlaith Ryan of Shorla said, "This significant investment will provide the necessary resource to further advance the product pipeline through health authority registration and commercialization which will ultimately create valuable and clinically impactful treatments that improve patient outcomes."  

Commenting about the support from Seroba, Sharon Cunningham added, "Seroba is a leading venture capital firm in the global life sciences industry and they, along with other participants in the investment syndicate bring invaluable experience to Shorla and have a proven track record in the pharmaceutical sector. We're confident that we have the right partners to support us in executing our vision."

Julie Sinnamon, CEO, Enterprise Ireland, said, "We are delighted to support Shorla and to be part of this investment round. Ireland is widely recognised as a center for the global life sciences industry as well as a leader in medtech and pharmaceutical manufacturing. Helping to maintain that reputation, Shorla, led by two female founders, is a highly innovative company developing new solutions to critical issues in the oncology area. It is also particularly heartening to see this company starting in a regional location. Earlier this year, the Enterprise Ireland 'Action Plan for Women in Business' cited that less than 10 percent of VC funding is going to companies with women founders. This investment is consistent with that action plan in terms of developing a larger number of companies of scale led by female founders. It is fantastic to have a role model like Shorla to demonstrate what's possible. I wish the team luck with the project and congratulate the company on its success to date."

About Shorla Pharma Ltd

Shorla Pharma Ltd is a privately held, Irish based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for women's and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or inadequate for the target population. Shorla's growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care. Shorla was established by Sharon Cunningham and Orlaith Ryan in 2018 and won the overall award at Ireland's Best Young Entrepreneur competition in 2019. Sharon and Orlaith were included on a list of 50 people to watch out for in 2020 by the Irish Times.

For further information, please visit www.shorlapharma.com

About Seroba Life Sciences

Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.

Follow our story at www.seroba-lifesciences.com

SOURCE Shorla Pharma


These press releases may also interest you

at 01:11
Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group", HKEx: 2318; SSE: 601318) is pleased to announce that its subsidiary Ping An Bank Co., Ltd. ("Ping An Bank") is ranked 46th in The Banker's Top 1000 World Banks, up nine...

at 01:08
APVG, an entity owned by EQT Infrastructure has entered into a new Scheme Implementation Agreement to acquire 100 percent of Metlifecare's shares The transaction consideration of NZD 6.00 per share gives a total consideration of approximately NZD1.3...

at 01:00
Merck, a leading science and technology company, opened its M Labtm Collaboration Center in Shanghai, the company's largest of nine centers...

at 00:01
ATTOM Data Solutions, curator of the nation's premier property database and first property data provider of Data-as-a-Service (DaaS), today released its second-quarter 2020 Special Report spotlighting county-level housing markets around the United...

9 jui 2020
South Carolina-based general contracting firm CRM ? Construction Management (CRM-CM) is excited to announce its services are now available in Brevard County, Florida in addition to South Carolina and North Carolina. This furthers the company's...

9 jui 2020
Aurora Spine Corporation ("Aurora Spine" or the "Company") announces financial results for the First Quarter 2020, ended March 31, 2020.  All figures are in U.S. dollars. To our Shareholders: Q1 2020 started strongly for the Company based on...



News published on 3 june 2020 at 03:00 and distributed by: